The global Chimeric Antigen Receptor T Cell Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chimeric Antigen Receptor T Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chimeric Antigen Receptor T Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Chimeric Antigen Receptor T Cell Therapy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Chimeric Antigen Receptor T Cell Therapy include Amgen, Bellicum Pharmaceuticals, Bluebird Bio, Caribou Biosciences, Celgene Corporation, Cellectis, Celyad Oncology, Gilead Sciences and Intellia Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chimeric Antigen Receptor T Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chimeric Antigen Receptor T Cell Therapy.
Report Scope
The Chimeric Antigen Receptor T Cell Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chimeric Antigen Receptor T Cell Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chimeric Antigen Receptor T Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Bellicum Pharmaceuticals
Bluebird Bio
Caribou Biosciences
Celgene Corporation
Cellectis
Celyad Oncology
Gilead Sciences
Intellia Therapeutics
Johnson & Johnson
Legend Biotech
Merck
Noile-Immune Biotech
Novartis
Pfizer
Sangamo Therapeutics
Servier Laboratories
Segment by Type
Allogeneic
Autologous
Segment by Application
Hospitals
Universities and Colleges
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chimeric Antigen Receptor T Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Allogeneic
1.2.3 Autologous
1.3 Market by Application
1.3.1 Global Chimeric Antigen Receptor T Cell Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Universities and Colleges
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Perspective (2019-2030)
2.2 Chimeric Antigen Receptor T Cell Therapy Growth Trends by Region
2.2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Region (2019-2024)
2.2.3 Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Region (2025-2030)
2.3 Chimeric Antigen Receptor T Cell Therapy Market Dynamics
2.3.1 Chimeric Antigen Receptor T Cell Therapy Industry Trends
2.3.2 Chimeric Antigen Receptor T Cell Therapy Market Drivers
2.3.3 Chimeric Antigen Receptor T Cell Therapy Market Challenges
2.3.4 Chimeric Antigen Receptor T Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chimeric Antigen Receptor T Cell Therapy Players by Revenue
3.1.1 Global Top Chimeric Antigen Receptor T Cell Therapy Players by Revenue (2019-2024)
3.1.2 Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Chimeric Antigen Receptor T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chimeric Antigen Receptor T Cell Therapy Revenue
3.4 Global Chimeric Antigen Receptor T Cell Therapy Market Concentration Ratio
3.4.1 Global Chimeric Antigen Receptor T Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chimeric Antigen Receptor T Cell Therapy Revenue in 2023
3.5 Chimeric Antigen Receptor T Cell Therapy Key Players Head office and Area Served
3.6 Key Players Chimeric Antigen Receptor T Cell Therapy Product Solution and Service
3.7 Date of Enter into Chimeric Antigen Receptor T Cell Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chimeric Antigen Receptor T Cell Therapy Breakdown Data by Type
4.1 Global Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Type (2019-2024)
4.2 Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Type (2025-2030)
5 Chimeric Antigen Receptor T Cell Therapy Breakdown Data by Application
5.1 Global Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Application (2019-2024)
5.2 Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chimeric Antigen Receptor T Cell Therapy Market Size (2019-2030)
6.2 North America Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2019-2024)
6.4 North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chimeric Antigen Receptor T Cell Therapy Market Size (2019-2030)
7.2 Europe Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2019-2024)
7.4 Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size (2019-2030)
8.2 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size (2019-2030)
9.2 Latin America Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2019-2024)
9.4 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size (2019-2030)
10.2 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Chimeric Antigen Receptor T Cell Therapy Introduction
11.1.4 Amgen Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.1.5 Amgen Recent Development
11.2 Bellicum Pharmaceuticals
11.2.1 Bellicum Pharmaceuticals Company Detail
11.2.2 Bellicum Pharmaceuticals Business Overview
11.2.3 Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Introduction
11.2.4 Bellicum Pharmaceuticals Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.2.5 Bellicum Pharmaceuticals Recent Development
11.3 Bluebird Bio
11.3.1 Bluebird Bio Company Detail
11.3.2 Bluebird Bio Business Overview
11.3.3 Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Introduction
11.3.4 Bluebird Bio Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.3.5 Bluebird Bio Recent Development
11.4 Caribou Biosciences
11.4.1 Caribou Biosciences Company Detail
11.4.2 Caribou Biosciences Business Overview
11.4.3 Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Introduction
11.4.4 Caribou Biosciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.4.5 Caribou Biosciences Recent Development
11.5 Celgene Corporation
11.5.1 Celgene Corporation Company Detail
11.5.2 Celgene Corporation Business Overview
11.5.3 Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Introduction
11.5.4 Celgene Corporation Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.5.5 Celgene Corporation Recent Development
11.6 Cellectis
11.6.1 Cellectis Company Detail
11.6.2 Cellectis Business Overview
11.6.3 Cellectis Chimeric Antigen Receptor T Cell Therapy Introduction
11.6.4 Cellectis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.6.5 Cellectis Recent Development
11.7 Celyad Oncology
11.7.1 Celyad Oncology Company Detail
11.7.2 Celyad Oncology Business Overview
11.7.3 Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Introduction
11.7.4 Celyad Oncology Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.7.5 Celyad Oncology Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Detail
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Introduction
11.8.4 Gilead Sciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.8.5 Gilead Sciences Recent Development
11.9 Intellia Therapeutics
11.9.1 Intellia Therapeutics Company Detail
11.9.2 Intellia Therapeutics Business Overview
11.9.3 Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Introduction
11.9.4 Intellia Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.9.5 Intellia Therapeutics Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Detail
11.10.2 Johnson & Johnson Business Overview
11.10.3 Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Introduction
11.10.4 Johnson & Johnson Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.10.5 Johnson & Johnson Recent Development
11.11 Legend Biotech
11.11.1 Legend Biotech Company Detail
11.11.2 Legend Biotech Business Overview
11.11.3 Legend Biotech Chimeric Antigen Receptor T Cell Therapy Introduction
11.11.4 Legend Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.11.5 Legend Biotech Recent Development
11.12 Merck
11.12.1 Merck Company Detail
11.12.2 Merck Business Overview
11.12.3 Merck Chimeric Antigen Receptor T Cell Therapy Introduction
11.12.4 Merck Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.12.5 Merck Recent Development
11.13 Noile-Immune Biotech
11.13.1 Noile-Immune Biotech Company Detail
11.13.2 Noile-Immune Biotech Business Overview
11.13.3 Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Introduction
11.13.4 Noile-Immune Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.13.5 Noile-Immune Biotech Recent Development
11.14 Novartis
11.14.1 Novartis Company Detail
11.14.2 Novartis Business Overview
11.14.3 Novartis Chimeric Antigen Receptor T Cell Therapy Introduction
11.14.4 Novartis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.14.5 Novartis Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Chimeric Antigen Receptor T Cell Therapy Introduction
11.15.4 Pfizer Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 Sangamo Therapeutics
11.16.1 Sangamo Therapeutics Company Detail
11.16.2 Sangamo Therapeutics Business Overview
11.16.3 Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Introduction
11.16.4 Sangamo Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.16.5 Sangamo Therapeutics Recent Development
11.17 Servier Laboratories
11.17.1 Servier Laboratories Company Detail
11.17.2 Servier Laboratories Business Overview
11.17.3 Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Introduction
11.17.4 Servier Laboratories Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2019-2024)
11.17.5 Servier Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Amgen
Bellicum Pharmaceuticals
Bluebird Bio
Caribou Biosciences
Celgene Corporation
Cellectis
Celyad Oncology
Gilead Sciences
Intellia Therapeutics
Johnson & Johnson
Legend Biotech
Merck
Noile-Immune Biotech
Novartis
Pfizer
Sangamo Therapeutics
Servier Laboratories
*If Applicable.